Endocyte And Accelerated Approval
Executive Summary
Endocyte CEO Ron Ellis shows no hard feelings that EC145 was turned down for accelerated approval, although he clearly thinks the PRECEDENT trial was well designed and that its median PFS results showed a sufficiently robust improvement over the control to warrant AA. Jason Kantor at RBC is not surprised. He says that, by FDA’s lights, robustness of data can mean different things: magnitude of variance, statistical rigor. “Endocyte showed benefit in a single trial – but that’s not as robust as when a larger Phase III trial confirms your findings.”
You may also be interested in...
Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market
With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.